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Introduction: Severe exacerbations associated with chronic obstructive pulmonary disease 
(COPD) that require hospitalization significantly contribute to morbidity and mortality. Defi-
nitions for exacerbations are very broad, and it is unclear whether there is one predominant 
underlying mechanism that leads to them. Functional respiratory imaging (FRI) with modeling 
provides detailed information about airway resistance, hyperinflation, and ventilation–perfusion 
(V/Q) mismatch during and following an acute exacerbation.
Materials and methods: Forty-two patients with COPD participating in a multicenter study 
were assessed by FRI, pulmonary function tests, and self-reported outcome measures during an 
acute exacerbation and following resolution. Arterial blood gasses and lung function parameters 
were measured.
Results: A significant correlation was found between alveolar–arterial gradient and image-
based V/Q (iV/Q), suggesting that iV/Q represents V/Q mismatch during an exacerbation 
(p,0.05).
Conclusion: Recovery of an exacerbation is due to decreased (mainly distal) airway resistance 
(p,0.05). Improvement in patient-reported outcomes were also associated with decreased 
distal airway resistance (p,0.05), but not with forced expiratory volume. FRI is, therefore, a 
sensitive tool to describe changes in airway caliber, ventilation, and perfusion during and after 
exacerbation. On the basis of the fact that FRI increased distal airway resistance seems to be 
the main cause of an exacerbation, therapy should mainly focus on decreasing it during and 
after the acute event.
Keywords: acute exacerbation, high-resolution computed tomography, functional respiratory 
imaging, ventilation–perfusion, airway resistance
Introduction
Exacerbation frequency has been increasingly used as an endpoint in clinical trials for 
obstructive lung diseases such as asthma and COPD. While an exacerbating episode 
is, without doubt, clinically relevant, the use of exacerbation frequency as a primary 
endpoint in clinical studies remains problematic. The definition of a respiratory exac-
erbation, per the Global Initiative for Chronic Initiative for Obstructive Lung Disease 
(GOLD) criteria, is very general and described as “an acute event characterized by 
a worsening of the patient’s respiratory symptoms that is beyond normal day-to-
day variations and leads to a change in medication.”1 In practice, this implies that a 
COPD exacerbation is typically diagnosed by the physician based on patient-reported 
changes in his or her symptoms rather than an objective threshold defined by changes 
in lung function (eg, spirometry) or by image-based parameters derived from CT or 
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magnetic resonance imaging. Confounding factors such as 
physical and psychological comorbidities can also influence 
the signal of this endpoint. Consequently, the signal-to-noise 
ratio is quite low and requires large clinical trials to ensure 
adequate statistical power. Another downside is that this 
endpoint requires a reliable baseline of the patient’s exac-
erbation rate, typically defined as at least two exacerbations 
per year. Often, the observed improvement in exacerbation 
rate, even in large clinical trials, is very limited in absolute 
value. Furthermore, a relatively long study duration is 
required to observe significant and relevant treatment effects 
using this endpoint.
Objective parameters are needed since they could also 
add prognostic value in clinical practice by predicting 
future exacerbating episodes. The latter could be achieved 
if parameters detect clinically relevant changes in structure 
and function in lungs that remain subsymptomatic during 
the in-between exacerbation periods. We believe that image-
based parameters including image-based airway resistance, 
regional flows, and perfusion giving an indication for lobar 
ventilation–perfusion ratio (V/Q)2 have the potential to be 
suchparameters. Oxygen uptake indeed depends on optimal 
ventilation and perfusion matching.
A hallmark feature of COPD patients, especially among 
those with an emphysematous phenotype, is the destruction 
of lung tissue resulting in altered vascularization and internal 
flow distribution, with potentially less airflow going to still 
well-perfused areas (Figure 1). This V/Q mismatch of3–5 has 
been associated with worsening of patient-reported outcomes 
(PROs) and exercise tolerance but, to our knowledge, has 
not been confirmed during exacerbation periods looking at 
the local changes in ventilation and perfusion; however, it is 
mainly derived from blood gas measurements that are sugges-
tive for increased alveolar–arterial oxygen gradient (AaDO
2
). 
A method that could, therefore, assess patient-specific V/Q 
ratio in a straightforward manner, preferably on a lobar basis, 
has high potential to be a relevant parameter and potentially a 
more objective descriptor of the pathophysiological changes 
during an exacerbation. It also has the potential to be a prog-
nostic factor. Lobar level seems relevant as many diseases 
exhibit patterns where either the upper lobes (eg, emphysema 
in COPD) or lower lobes (eg, emphysema in α1 antitrypsin 
deficiency or fibrosis in idiopathic pulmonary fibrosis) are 
initially affected, followed by a spreading of the disease to 
the other lobes.
Our group has developed a method called functional 
respiratory imaging (FRI) that addresses the call for more 
objective parameters. FRI is a combination of high-resolution, 
low-dose, volumetric CT scans and computational fluid 
dynamics (CFD). FRI provides regional details associated 
with lung structure and function. In previous studies, we 
demonstrated the capabilities of FRI to provide accurate 
parameters related to ventilation, perfusion, and tissue 
characteristic.6,8 As such, FRI has emerged as a powerful 
tool to assess bronchodilation, vasodilation, and changes in 
internal flow distribution and, based on that, inhaled aerosol 
deposition.
The aim of this study was to examine exacerbations 
in COPD patients using FRI to better understand altera-
tions in lung structure and function due to the exacerbating 
episode.
Materials and methods
A total of 42 patients with COPD participating in a mul-
ticenter trial (NCT01684384) were included in this study. 
COPD was defined by the GOLD criteria. Patients had 
documented histories of postbronchodilator forced expira-
tory volume (FEV
1
)/forced vital capacity (FVC) ,70% and 
postbronchodilator FEV
1
 ,80% predicted in the last 5 years 
and smoking histories of at least 10 pack-years. At entry 
into the study, experiencing an exacerbation was defined 
as an acute change in a patient’s baseline dyspnea, cough, 
and/or sputum that was beyond normal day-to-day varia-
tions and that necessitates the administration or doubling 
of systemic corticosteroid treatment. Patients diagnosed 
with asthma, pneumonia as defined radiologically at the 
start of the exacerbation, and/or a history of lung cancer 
Figure 1 Functional respiratory imaging can describe vascular structures and blood 
vessel density as well as lobe and lung expansion and, therefore, indicate the image-
based ventilation–perfusion ratio.
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were excluded. Patients with an indication for noninvasive 
ventilation were also excluded, as we know that this can alter 
airway geometries.
Patients underwent two low-dose high-resolution com-
puted tomography (HRCT), one during an exacerbation and 
another 6–8 weeks after the recovery from the episode. During 
the scan sessions, one scan was taken at total lung capacity 
(TLC), the lung level attained after deep inspiration, and 
another was taken at functional residual capacity (FRC), the 
lung volume attained after a normal expiration. A handheld 
pneumotachograph was used for volume-gating purposes to 
ensure scans were taken at the correct lung level. A pneumot-
achograph has limitations because it only gives relative vol-
ume values and not absolute volume values. The HRCT scans 
were then processed using the FRI approach, which quantifies 
lobar volumes (iVlobes) at both lung volumes also providing 
internal airflow distribution, airway volumes (iVaw), airway 
resistance (iRaw), and blood vessel volumes (iVbv). In addi-
tion to the scans, spirometry was performed and patients 
completed a range of PROs, including the COPD Assess-
ment Test (CAT) and Modified Medical Research Council 
Dyspnea scale. Arterial blood gases were obtained at baseline 
in a subset of patients not taking oxygen and in all patients 
during recovery without oxygen.
The study protocol was approved by the Ethical Commit-
tee of the University Hospital of Antwerp (14/35/361), and 
written informed consent was given by each patient at the 
time of entry to the study. All procedures performed in this 
study were in accordance with the ethical standards of the 
institutional research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical 
standards. The clinical trial registration number for this study 
is NCT01684384.
Functional respiratory imaging
HRCT images were imported into Mimics, a commercial, 
US Food and Drug Administration-approved, medical image 
processing software package (Materialise, Leuven, Belgium, 
Food and Drug Administration, K073468; CE certificate, BE 
05/1191 CE01). This software package converts the HRCT 
images into patient-specific, three-dimensional (3D) com-
puter models of the lung lobes and the airway tree, which 
can be segmented down to bronchi with a diameter of about 
1–2 mm. The 3D models were converted in a computational 
grid using a commercial software package. Mesh size was 
about 4.5×106 cells. Steady flow simulations on these grids 
were performed using a commercial CFD solver. The airway 
tree was evaluated at TLC and at FRC. CT scans are taken 
using a dose-reduction protocol (120 kV, 10–100 mAs; noise 
factor 28; collimation 0.625 mm; rotation time 0.6 s; and 
pitch factor 1.375), resulting in an effective dose of 1–2 mSv 
per CT scan. The scan resolution is 0.5 mm3, and the slice 
increment is 0.6 mm.
A mass flow of 30 L/min was specified as a boundary 
condition at the trachea to reflect normal tidal breathing. At 
the outlets, the static pressure was defined using an iterative 
process to reflect the internal mass flow distribution matching 
the lobar expansion as derived from the CT data. The flow 
was considered laminar, incompressible, and adiabatic. The 
local airway resistance (iRaw) was obtained from the CFD 
data and defined as iRaw = Δp/F, where Δp equals the total 
pressure drop over a certain region and F equals the mass 
flow rate of air through this region.
FrI assessment of blood vessel density
Blood vessel density can be determined through segmentation 
and 3D reconstruction of the blood vessels. Segmentation is 
based on a Hounsfield unit (HU) threshold of [-600; 600] 
and is performed on the TLC scan. Blood vessel density can 
be considered a surrogate for perfu sion, as outlined in the 
study by De Backer et al.9 These insights allow us to study 
the localization of emphysema and V/Q mismatch in COPD 
patients. We calculated perfusion and ventilation separately 
for each lobe. Image-based perfusion (iQ) was calculated by 
blood vessel density at TLC multiplied by image volume at 
TLC. Image-based ventilation (iV) was calculated by image-
based volume at TLC minus the image-based volume at FRC. 
This was calculated for the five lobes separately. The mean 
value of image-based ventilation–perfusion match (iV/Q) 
for each individual patient was calculated.
Statistical analysis
Statistical analysis was performed using the Statistica (Sta-
tistica 13, Statsoft, Dell, Tulsa, OK, USA). Spearman rank 
order correlations were performed between parameters that 
were measured on a lobar basis. Significance level was set 
at p,0.05.
Results
A total of 54 patients were enrolled (intention to treat popula-
tion) in the clinical trial (NCT01684384) between October 
2012 and August 2014 in Belgium (N=38), the Netherlands 
(N=6), and Italy (N=10). Forty-two patients were evaluated 
in this study as per protocol analysis. Twelve patients were 
excluded because of clinical and technical reasons (pneumo-
nia, need of Bipap, second CT scan could not be taken, or data 
were missing). Not all the test could be performed in all the 
patients at both visits. All the patients started with systemic 





corticosteroids treatment after admission to the hospital. 
About 55% were male (N=23) with a mean age of 68 years and 
a mean FEV
1
 of 1.13 L. Descriptive data are listed in Table 1. 
The changes in FEV
1
, FRC, and TLC between visit 1 and visit 
2 are listed in Table 2. FEV
1
 significantly increased at recovery 
(p,0.001), FRC significantly decreased at recovery (p=0.02), 
and TLC remained unchanged. The iV/Q ratio derived from 
the HRCT scans significantly correlated with AaDO
2
 (p=0.01; 
Figure 2). It was found that iV/Q significantly improved after 
recovering from an exacerbation (p,0.05). Improvement 
in iV/Q correlated with increased lung expansion (p=0.00, 
Figure 3). Lung expansion is the difference at lobar level 
between FRC and TLC volumes measured by imaging (iV). 
No such correlation was found with changes in the imaged 
perfusion surrogate (iQ). Hence, the improvement in iV/Q is 
mainly driven by the improvement in iV.
Central airway resistance and distal airway resistance 
both declined after an exacerbation. The increased lung 
expansion significantly correlated with improved distal 
airway resistance (Figure 4, p=0.03) and with improved 
central airway resistance (Figure 5, p=0.00). Changes in 
FRI-based distal airway resistance (iRaw distal) measured 
at FRC significantly correlated with changes in the PROs, 
mainly CAT (Figure 6, p=0.04) and mMRC (p=0.00). 
No association was found between patients’ improvement 
in FEV
1
 and their PROs (Figure 7).
Discussion
We observed that the increase in distal airway resistance 
mainly leads to hyperinflation and V/Q mismatch during the 
exacerbation. Further, changes in perfusion only partially 
contribute to the observed worsening in V/Q. The changes 
in distal airway resistance correlated with the PROs, which 
was not the case for the lung function tests. Enhanced distal 
airway inflammation seems to be the main driver of the 
exacerbation and, therefore, also the most important target 
for treatment. For the first time, HRCT data and CFD have 
been used to understand the pathophysiological changes 
that take place during a COPD exacerbation. FRI provided 
deeper insight into regional changes in distal bronchial and 
central bronchial airway resistance and the V/Q ratio during 
an exacerbation and in the recovery phase. One of the major 
limitation of the study is it’s small sample size; thereby, the 
findings of this study may or may not be conclusive or gen-
eralizable to other COPD patients. To confirm the results of 
this study, a larger-scale study has to be implemented.
Small airways are usually defined as noncartilaginous 
conducting airways with an internal diameter ,2 mm (corre-
sponding to approximately eight generations of airways down 
to the terminal and respiratory bronchioles) and alveoli.10,11 
We looked at distal airways (starting from the fourth gen-
eration until the seventh to eighth generation) since these 
airways include almost all the airway resistance (Figure 8). 
A characteristic finding in COPD subjects with severe airflow 
limitation (GOLD stages III and IV) is increased epithelial 
thickness, probably related to squamous metaplasia and 
goblet cell hyperplasia.12 An increase in airway resistance 
can be caused by a range of mechanisms such as respiratory 
infection, cardiac failure, or emotional distress and is not 
well defined by traditional lung function measurements.13 
A retrospective review of patients who underwent spirom-
etry and static lung volume measurements before and after 
the administration of 200 µg salbutamol showed that FEV
1
 
Table 1 Patient characteristics
Patient characteristics
number of patients: M/F (male/female) 23/19
age (years) 68 (±9.71)
COPD GOlD II (FeV1 80%–50%) 17
COPD GOlD III (FeV1 50%–30%) 19
COPD GOlD IV (FeV1 ,30%) 6
IC (l) 1.92 (±0.45)
IC (%pred) 61.6 (±0.61)
IC/TlC (%pred) 30.1 (±0.89)
FeV1 (%pred) 46 (±14.53)
FeV1/FVC (%)
a 42 (±12.04)
FeV1 (l) 1.13 (±0.39)
TlC (l) 6.78 (±1.41)
TlC (%pred) 1,175 (±18.9)
FrC (l) 4.88 (±1.35)
FrC/TlC (%pred) 71.2 (±1.24)
raw (kPa s/l) 0.54 (±2.01)
pCO2 (kPa) 5.3 (±4.83)
pO2 (kPa) 8.9 (±8.64)
mMrC score 3.0 (±1.14)
CaT score 34.4 (±8.01)
Notes: Values are shown as mean ± SD. aFeV1/FVC (%): fifth percentile of reference 
population.
Abbreviations: CaT, COPD assessment test; FeV1, forced expiratory volume in 
1 second; FVC, forced vital capacity; FeV1/FVC, Tiffeneau index; FrC, functional 
residual capacity; GOlD, Global Initiative for Chronic Initiative for Obstructive 
Lung Disease; IC, inspiratory capacity; mMRC, modified Medical Research Council 
dyspnea scale; raW, airway resistance; TlC, total lung capacity.
Table 2 Changes in FeV1, FrC, and TlC between visit 1 and 
visit 2
V1 V2
FeV1 (%pred) 46 (±15.36) 52 (±16.99)
FrC (l) 4.8 (±1.32) 4.6 (±1.18)
TlC (l) 6.78 (±1.45) 6.78 (±1.32)
Note: Values are shown as mean ± SD.
Abbreviations: FeV1, forced expiratory volume in 1 second; FrC, functional 
residual capacity; V1, visit 1 (admission); V2, visit 2 (recovery); TlC, total lung 
capacity.
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is an insensitive marker for bronchodilator responsiveness 
and is especially unable to predict improvement in symp-
toms or exercise tolerance.14 Lung hyperinflation correlates 
better with dyspnea and health status than with FEV
1
 and is 
responsible for excessive loading and functional weakness 
of inspiratory muscles.15–17
Our findings using FRI indicate that treatment of an exac-
erbation should be focused on improvement of distal bronchial 
airway resistance. However, measurement of distal bronchial 
airway resistance in patients with COPD has proven difficult 
to explore. An invasive technique that involves an esophageal 
balloon to measure pleural pressure can be used to calculate 
the total pulmonary resistance. Forced oscillations techniques 
and multiple nitrogen washout tests have the disadvan-
tage of inconsistent reliability18,19 and lack spatial resolution.
FRI provides deeper insight as the static images obtained 
with CT can be made more functional by means of CFD. CFD 















     
Figure 2 There is a significant correlation (Spearman rank order R=-0.47, p=0.02) between iV/Q (at visit 2) and aaDO2 (at visit 2) indicating that iV/Q reflects ventilation–
perfusion mismatch.






















            
Figure 3 There is a significant correlation between the improvement in lung expansion (the difference at lobar level between FRC and TLC volumes) and the improvement 
in iV/Q (Spearman rank order r=0.51, p=0.00) indicating that the improvement in iV/Q is due to improved ventilation at the lobar level.
Abbreviations: FrC, functional residual capacity; iV/Q, image-based ventilation–perfusion; TlC, total lung capacity.





accurate boundary conditions. The process is also relatively 
simpler and significantly less invasive. Patients undergo two 
low-dose HRCT scans with respiratory gating, performed at 
FRC and TLC. A combination of increased speed and reduced 
slice thickness makes it possible to scan the patient during 
one breath hold and subsequently reconstruct the airway 
geometry in a 3D computer model up to the distal airways. 
FRI provides details of the ventilation, perfusion, and depo-
sition of inhaled drugs.7,9,17,20–27 Regional airway resistance 
and impedance can also be measured with FRI. The airways 
can be segmented up to the point where no distinction can 
be made between the intraluminal and alveolar air. This is 
where the airway diameter is about 1–2 mm, typically around 
the fifth to tenth bifurcation, depending mainly on the disease 
state of the individual patient. From the resulting model, the 
central and distal airway volumes (iVaw) can be assessed 
at individual airways or within different regions. The distal 
airway volume is defined as the segmented airway volume 
starting from the third bifurcation.28 For the boundary condi-






















            
Figure 4 Correlation between the improvement in lung expansion (as a sum of lobar expansion; Spearman rank order r=-0.34, p=0.03) after recovery and distal airway 
resistance (measured at TlC) after recovery (at visit 2).
Abbreviation: TlC, total lung capacity.
Figure 5 Correlation between lung expansion (Spearman rank order r=-0.53, p=0.00) after recovery and central airway resistance (at TlC) after recovery (at visit 2).
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Figure 6 Correlation between the improvement in CaT score (Spearman rank order r=0.33, p=0.04) and the drop in distal airway resistance (at FrC) after recovery.





























   
Figure 7 absence of correlation between the improvement in FeV1 and the improvement in CaT score (Spearman rank order r=-0.25, p=0.12).





















   
at 25–30 L/min to simulate tidal breathing. The outflow to 
each lobe is adjusted iteratively for each patient to match the 
internal flow rate distributions obtained from the segmenta-
tion of the CT scans. The airflow distribution in the computer 
model reflects the airflow distribution as derived from the 
expansion of the lung lobes from FRC to TLC. This way, 
airway resistance (iRaw), defined as the total pressure drop 
over an airway, divided by the flow rate through that airway, 
in individual airways or different regions can be obtained 
from the CFD calculations (Figure 8).
Distal airways abnormalities are found early during 
COPD, and this provides a rationale for early therapy tar-
geting these airways. Yanai et al29 showed that distal airway 
resistance was significantly increased in patients with chronic 
airflow obstruction. Despite recognition that distal airways 
are important in the pathophysiology of COPD, current 
inhaled therapies mostly deposit in proximal airways.30 In our 
patients, there was significant improvement in distal resis-
tance in the recovery phase of an exacerbation. Better treat-
ment strategies for patients with COPD include the delivery 





Figure 8 relationship between airway resistance and airway generation.
Notes: The largest part of the airway resistance is located before the ninth generation. reproduced with permission from The radiological Society of north america (rSna), 
De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257(3):854–862.20








































                   
of oral medications or inhaled medication using extra-fine 
particles, which are known to deposit in both proximal and 
distal airways, as opposed to non-extra-fine particles, which 
deposit predominantly in proximal airways.
Other possible methods to improve distal bronchial airway 
resistance are systematic effective anti-inflammatory thera-
pies. Roflumilast is a novel phosphodiesterase 4 inhibitor that 
has been shown to induce a modest increase in FEV
1
 and to 
reduce mainly severe COPD exacerbations in specific sub-
groups of patients with COPD.9,27,31,32 In a previous study, we 
demonstrated that orally administered Roflumilast supported 
the reduction of regional hyperinflation in areas previously 
undertreated by inhalation medication.27 The local reduc-
tion in hyperinflation induced a redistribution of ventilation 
and aerosol deposition, leading to the enhanced efficacy of 
the concomitant ICS/LABA/LAMA therapy. Reducing the 
airway resistance could also be established by increasing the 
intraluminal airway pressure with noninvasive ventilation 
(NIV). NIV effects in chronic hypercapnic COPD patients 
were studied using FRI to identify the mechanism behind 
the beneficial effect and to investigate if there were different 
responder groups.25 A mass flow redistribution occurred in 
patients treated with long-term NIV over 6 months, providing 
a better V/Q match and, hence, better blood gases and lung 
function in patients with a blood vessel density of .9%. 
Control patients improved homogeneously in iVaw and 
iRaw, but no changes were found in gas exchange, and so 
no increase in V/Q ratio or alveolar ventilation was seen. 
This led us to conclude that only patients with localized 
small airway disease may be good candidates for long-term 
NIV treatment.
In our opinion, all currently available inhaled drugs may 
have effects on distal bronchial airways if they can reach 
them. Opening the distal bronchial airways by systemic 
therapy, inhaled therapy, and/or airway clearance techniques 
is the adequate treatment for a COPD exacerbation and 
maintenance therapy. This study supports the role of the 
distal airway in the exacerbation period.
Structural abnormalities are not only limited to small 
conducting airways and alveoli but also extend to small 
pulmonary arteries (diameter ,500 µm). Abnormalities 
in pulmonary arteries can also be found in patients with 
moderate COPD and in smokers with normal lung func-
tion, suggesting that these abnormalities may originate 
at an early stage in cigarette smoke-induced respiratory 
disease.33 Abnormalities in pulmonary arteries may result 
in gas exchange impairment and, in a minority of patients, 
in pulmonary hypertension.7,34 HRCT can also determine 
vasculature by calculating the percentage of voxels in a 
lobe that lie in the (-600, 600) HU range, a measure of the 
electron density of the tissue. Furthermore, the severity of 
emphysema can also be correlated with a decrease in local 
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HU, indicating a destruction in pulmonary lung tissue. These 
insights in perfusion allow us to study the localization of 
emphysema in COPD patients7 and their V/Q match. In our 
study, there was a significant correlation between iV/Q and 
AaDO
2
, indicating that the iV/Q represents V/Q mismatch. 
Improvement of the iV/Q at recovery of an exacerbation 
appears mainly driven by lobar expansion, indicative of better 
ventilation with minimal change in perfusion. No significant 
changes in the blood vessel density were observed. The iV/Q 
is still only a surrogate marker for the real V/Q mismatch, 
and the units used in this study are driven by the units used 
for the blood vessel density and, therefore, not representative 
for the real V/Q units. However, given the good correlation 
with the AaDO
2
, it can probably be used in a more systematic 
way to obtain insight in the relative contribution of the airway 
component (reflected in the iV factor) and the vascular com-
ponent (reflected in the iQ factor). In this study, we mainly 
observed changes in iV as driver for the V/Q mismatch, but 
it might well be that at the individual level and larger scale 
some patients do present with an exacerbation clinic driven 
by the iQ factor. That would, of course, have therapeutic 
implications.
Improvement in the PROs did not correlate with changes 
in FEV
1
. On the contrary, distal bronchial airway resistance 
was significantly associated with patients’ self-reported 
symptoms (Figure 6). Change in FRI-based distal bronchial 
airway resistance at FRC correlated with the change in CAT 
and mMRC dyspnea scores. We can conclude from these 
results that distal bronchial airways are a major site of airflow 
limitation in COPD patients during an exacerbation and have 
a direct impact on their perceived symptoms. We consider 
this as an important finding from this study.
Conclusion
Therapeutic interventions should be aimed at improving 
distal bronchial airway resistance, especially during COPD-
associated exacerbations. iV/Q helps us better understand 
the pathophysiology of COPD exacerbations and other 
effects of complex pulmonary diseases. The correlation 
with iV/Q and blood gases is not perfect, but the trends are 
there, and in fact we were impressed that regional informa-
tion coming from CT images can explain the V/Q mismatch 
in a meaningful way. This indeed may also help us when 
looking for the “regional” cause of the hypoxemia. FRI is a 
compatible tool to determine the underlying mechanisms that 
lead to exacerbations as well as the potential effectiveness 
of a treatment by providing a highly sensitive and detailed 
description of airway resistance. Future studies using this 
tool may further confirm this approach that has the potential 
to substantially improve the diagnosis and treatment of the 
exacerbation.
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